AptarGroup, Inc.

AptarGroup, Inc.

ATR
AptarGroup, Inc.US flagNew York Stock Exchange
128.31
USD
-2.02
- -
8.19BMarket Cap
AptarGroup, Inc.
ATR
(New York Stock Exchange)

Recent

price

128.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
30.84
35.12
35.11
38.13
39.96
37.02
37.11
39.55
44.28
44.98
45.47
49.15
50.8
53.15
54.01
57.46
45
Revenue per Share
2.58
2.76
2.45
2.6
2.95
3.19
3.27
3.52
3.12
3.81
3.32
3.72
3.66
4.34
5.65
5.97
4.26
Basic EPS, GAAP
4.13
3.92
4.73
4.32
4.87
5.17
5.14
5.2
5.01
8.02
8.76
5.53
7.24
8.67
9.43
8.59
7.41
Free Cash Flow per Basic Share
0.66
0.8
0.88
1
1.09
1.14
1.22
1.28
1.32
1.42
1.44
1.5
1.52
1.58
1.72
1.84
1.43
Dividend per Share
19.15
19.57
20.94
22.63
17.8
18.39
18.9
21.23
22.62
24.64
28.47
30.07
31.5
35
37.17
41.55
- -
Book Value per Share
15.67
15.96
14.82
16.38
11.83
12.92
10.82
12.5
7.24
8.11
9.35
9.66
12.16
16.09
19.26
20.79
- -
Tangible Book Value per Share
67
67
66
66
65
63
63
62
62
64
64
66
65
66
66
66
65
Basic Weighted Avg Shares
2,077
2,337
2,331
2,520
2,598
2,317
2,331
2,469
2,765
2,860
2,929
3,227
3,322
3,487
3,583
3,777
2,907
Sales/Revenue/Turnover
12.91
12.28
11.24
11.76
11.8
13.99
13.46
13.19
12.66
13.71
12.49
11.48
11.61
12.88
14.22
13.53
12.32
Operating Margin (%)
133
134
137
150
152
139
155
153
172
195
220
235
234
249
264
287
228
Depreciation Expense
173
184
163
172
192
199
206
220
195
242
214
244
239
284
375
393
275
Net Income, GAAP
31.76
33.21
32.71
34.97
33.07
32.34
26.7
25.37
26.79
29.19
28.91
24.25
28.43
24.18
20.35
20.12
19.02
Effective Tax Rate (%)
8.35
7.86
6.98
6.83
7.38
8.6
8.82
8.91
7.04
8.47
7.31
7.56
7.2
8.16
10.45
10.4
9.46
Profit Margin (%)
641
625
584
656
609
883
727
1,142
642
608
589
376
513
298
410
727
- -
Working Capital
259
255
353
355
589
761
773
1,191
1,126
1,141
1,107
955
1,096
726
738
1,187
- -
LT Debt
1,280
1,291
1,380
1,480
1,104
1,150
1,174
1,312
1,423
1,572
1,851
1,985
2,068
2,321
2,486
2,712
- -
Total Equity
11.41
11.46
10.01
10.22
10.49
11.23
11.26
10.38
9.72
10.05
8.84
8.92
8.5
10.06
11.54
10.5
15.12
Return on Invested Capital (%)
11.36
11.61
9.93
9.8
10.5
11.39
11.32
10.67
8.28
9.66
8.06
8.48
8.23
9.29
11.6
11.15
16.27
Return on Capital (%)
13.7
14.3
12.18
12.03
14.84
17.7
17.7
17.7
14.24
16.18
12.51
12.78
11.89
13.05
15.68
15.28
20.37
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
344
222
- -
LT Borrowings
1,139
1,143
- -
LT Finance Leases
48
44
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
64
Market Capitalization
7,831
8,053
8,000

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,894
1,768
- -
Cash, Cash Equivalents & STI
410
229
- -
Accounts Receivable, Net
804
833
- -
Inventories
538
551
- -
Total Current Liabilities
1,166
1,063
- -
Payables & Accruals
515
841
- -
ST Debt
344
222
- -
Deferred Revenue
75
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.04%
7.97%
9.1%
Free Cash Flow
8.53%
3.03%
-9.71%
Net Income, GAAP
7.89%
13.5%
4.87%
Sales/Revenue/Turnover
5.06%
5.25%
5.42%
Total Cash Common Dividend
5.46%
5.48%
5.9%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
915
910
909
848
3,583
2025
887
966
961
963
3,777
2026
983
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.26
1.36
1.51
1.52
5.65
2025
1.19
1.69
1.95
1.14
5.97
2026
1.13
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
0.41
0.45
0.45
1.72
2025
0.45
0.45
0.45
0.48
1.84
2026
0.48
- -
- -
- -
- -
Business
AptarGroup, Inc. designs, manufactures and markets a broad range of drug delivery systems, consumer product dispensing systems, active material science solutions and sealing, packaging services for the pharmaceutical, beauty, personal care, home care, food and beverage industries worldwide. The company operates through three main segments: Aptar Pharma, which provides nasal and pulmonary drug delivery devices including pumps for nasal allergy treatments, metered-dose inhaler valves for respiratory conditions such as asthma and chronic obstructive pulmonary disease, elastomers for injectable packaging components, proprietary Unidose and Bidose intranasal delivery systems, aerosol valves, digital health solutions and clinical trial materials manufacturing services; Aptar Beauty, which offers dispensing pumps, closures, pouch spouts, spray pumps and valves for fragrance, make-up, skincare and cleansing products; and Aptar Closures, which supplies dispensing closures, dosing cups, droppers and other packaging solutions. AptarGroup sells its products primarily in North America, Europe, Asia and Latin America; the company was incorporated in 1992 and maintains headquarters in Crystal Lake, Illinois, with manufacturing facilities and over 13,000 employees across 20 countries. Recently, Aptar Pharma acquired the device technology assets of SipNose Nasal Delivery Systems in November 2025 to expand its intranasal drug delivery portfolio for local, systemic and central nervous system indications including nose-to-brain pathways; acquired clinical trial materials manufacturing capabilities of Mod3 Pharma in July 2025 to enhance Phase 1 and 2 formulation, fill-finish services for orally inhaled and nasal drug products at an FDA-inspected facility in Boonton, New Jersey; acquired Brazilian pharmaceutical packaging firm Sommaplast in December 2025 to strengthen oral dosing solutions such as closures, droppers, dispensers and dosing cups amid growth in over-the-counter and nutraceutical markets; issued approximately $600 million in senior unsecured notes due 2031 in November 2025 to bolster financial flexibility for operations and acquisitions; and extended collaboration with Nasus Pharma on intranasal epinephrine devices.

Company News

  • CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

  • Callan Family Office LLC Makes New Investment in AptarGroup, Inc. $ATR

  • Deutsche Bank AG Invests $14.90 Million in AptarGroup, Inc. $ATR

  • Aurora Investment Counsel Acquires New Stake in AptarGroup, Inc. $ATR

  • Dividend Champion, Contender, And Challenger Highlights: Week August 16

  • Atrium Therapeutics Reports Second Quarter 2026 Financial Results

  • AptarGroup, Inc. $ATR Shares Acquired by Bank of America Corp DE

  • AptarGroup Q2 Earnings Beat Estimates on Pharma & Beverage Growth

  • AptarGroup, Inc. $ATR Stock Position Raised by California State Teachers Retirement System

  • AptarGroup, Inc. (NYSE:ATR) Receives Average Recommendation of “Moderate Buy” from Brokerages

  • Why AptarGroup (ATR) International Revenue Trends Deserve Your Attention

  • AptarGroup, Inc. (ATR) Q2 2026 Earnings Call Transcript

  • AptarGroup Q2 Earnings Call Highlights

  • AptarGroup (ATR) Tops Q2 Earnings and Revenue Estimates

  • AptarGroup Inc (ATR) Stock Up 3.3% and Still Undervalued -- GF Score: 82/100

  • Aptar Named One of the World's Most Sustainable Companies by TIME for Third Consecutive Year

  • First Trust Advisors LP Acquires 160,763 Shares of AptarGroup, Inc. $ATR

  • AptarGroup (ATR) Expected to Beat Earnings Estimates: Should You Buy?

  • Aptar Beauty Launches Next-Generation Auto-Loading Dropper Technology for Easier, More Accurate Skincare Dosing

  • Chicago Partners Investment Group LLC Invests $505,000 in AptarGroup, Inc. $ATR